Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study
JavaScript is disabled for your browser. Some features of this site may not work without it.
Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study
DEMİRKAZIK, AHMET; Turhal, Nazim Serdar; Bozcuk, Hakan; COŞKUN, HASAN ŞENOL; ENGİN, HÜSEYİN; ARTAÇ, MEHMET; Korkmaz, Levent; Dede, Isa; Oksuzoglu, Berna; PAYDAŞ, SEMRA; Kocer, Murat
Survival outcomes of interferon-alfa and tyrosine kinase inhibitors for 104 cases of metastatic renal cell carcinoma were included in this study. First-line interferon-alfa treatment before tyrosine kinase inhibitors had an additive survival affect.